• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drug & Device Pipeline News

Drug & Device Pipeline News

December 13, 2021
Company Drug/Device Medical Condition Status
Trials Authorized
Acer Therapeutics ACER-801 (osanetant) Induced vasomotor symptoms IND approved by the FDA
ChemomAb CM-101 Primary sclerosing cholangitis IND approved by the FDA
Cyclo Therapeutics Trappsol Cyclo Early Alzheimer’s disease IND approved by the FDA
MingMed Biotechnology PRJ1-3024 Cancer IND approved by the FDA
Nuvation Bio NUV-422 Advanced breast cancer IND approved by the FDA
Ocugen OCU400 (AAV-NR2E3) Retinitis pigmentosa resulting from genetic mutations in NR2E3 or RHO genes IND approved by the FDA
Biotheus PM8001 Advanced solid tumors Phase 2 trial approved by the FDA
Trials Initiated
Biofrontera Ameluz photodynamic therapy Actinic keratosis Initiation of phase 1 trial
Celldex Therapeutics CDX-0159 Prurigo nodularis Initiation of phase 1 trial
Iterion Therapeutics Tegavivint in combination with osimertinib Metastatic epidermal growth factor receptor-positive nonsmall-cell lung cancer Initiation of phase 1 trial
Tranquis Therapeutics TQS-168 Neurodegenerative disease Initiation of phase 1 trial
Affimed AFM24 in combination with atezolizumab Solid tumors Initiation of phase 1/2 trial
MRM Health MH002 Mild-to-moderate ulcerative colitis Initiation of phase 1b/2a trial
Springworks Therapeutics Nirogacestat Multiple myeloma Initiation of phase 1b/2 trial
Hepagene Therapeutics HPG1860 Nonalcoholic steatohepatitis Initiation of phase 2a trial
Karyopharm Selinexor Myelofibrosis Initiation of phase 2 trial
Ventyx Biosciences VTX002 Moderate-to-severe ulcerative colitis Initiation of phase 2 trial
Vir Biotech

Gilead Sciences
VIR-2218, selgantolimod and nivolumab Chronic hepatitis B virus infection Initiation of phase 2 trial
ZZ Biotech 3K3A-APC Amyotrophic lateral sclerosis Initiation of phase 2 trial
Acurx Pharmaceuticals Ibezapolstat Clostridioides difficile infection Initiation of phase 2b trial
Checkpoint Therapeutics Cosibelimab in combination with chemotherapy First-line treatment of patients with nonsquamous nonsmall-cell lung cancer Initiation of phase 3 trial
DyDo Pharma Firdapse (amifampridine) Lambert-Eaton myasthenic syndrome Initiation of phase 3 trial in Japan
Approvals
Daré Biosciences Xaciato (clindamycin phosphate vaginal gel, 2%) Bacterial vaginosis in females under 12 years of age Approved by the FDA
Eli Lilly

Junshi
Etesevimab (JS016/LY-CoV016) and bamlanivimab (LY-CoV555) Treatment of mild-to-moderate COVID-19 and postexposure prophylaxis in certain high-risk pediatric patients from birth to 12 years of age Emergency Use Authorization expanded by the FDA
Heron Therapeutics Zynrelef (bupivacaine and meloxicam) extended-release solution Soft tissue or periarticular instillation in adults to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures Approved by the FDA for expanded indication
Merck Keytruda (pembrolizumab) Stage IIB or IIC melanoma following complete resection in patients under age 12 Approved by the FDA for expanded indication
Octapharma Cutaquig immune globulin, subcutaneous (human)-hipp 16.5% solution Primary humoral immunodeficiency in patients under age two Approved by the FDA for expanded indication
Beigene

EUSA
Sylvant (siltuximab for injection) Idiopathic multicentric Castleman disease Approved in China

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing